March 17, 2022 -- BeiGene has received a new conditional approval from the China National Medical Products Administration (NMPA) for its tislelizumab anti-programmed cell death 1 (PD-1) monoclonal antibody.
The NMPA approved the use of tislelizumab as a treatment for advanced unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors in adult patients. The approval covers patients with advanced colorectal cancer who had been treated with fluoropyrimidine, oxaliplatin, and irinotecan, according to the vendor. It also covers patients with other advanced solid tumors who developed disease progression after prior treatment and have no satisfactory alternative treatment options, BeiGene said.
With the new approval, tislelizumab has now been cleared in China for seven indications, according to the firm.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
